ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,930.85
1.09%
Dow Jones
42,840.26
1.18%
US Dollar vs MXN
20.09125
0.10%
Brent Oil
72.655
-0.08%
Bitcoin
96,128.43
1.07%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Alpha Tau Medical Ltd (DRTS) Cotización

Alpha Tau Medical Ltd

Alpha Tau Medical Ltd (DRTS)

NASDAQ
3.10
-0.03
(-0.80%)
Cerrado 20 Diciembre 3:00PM
Delayed by 15 minutes
3.10
0.00
( 0.00% )
Pre Mercado: 3:05AM
Delayed by 15 minutes

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Estadísticas y detalles clave

Último Precio
3.10
Postura de Compra
3.00
Postura de Venta
4.94
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
1.75 Rango de 52 semanas 3.40
Capitalización de Mercado [m]
215.979M
Precio Anterior
3.10
Precio de Apertura
-
Hora
Última hora de negociación
-
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
35,619
Acciones en circulación
69,670,612
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-7.41
Beneficio por acción (BPA)
-0.42
turnover
-
Beneficio neto
-29.16M

Acerca de Alpha Tau Medical Ltd

Alpha Tau Medical focuses on R&D, and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid cancer tumors. The Alpha DaRT technology was developed in 2003 at Tel Aviv University. Alpha Tau Medical focuses on R&D, and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid cancer tumors. The Alpha DaRT technology was developed in 2003 at Tel Aviv University.

Sector
Surgical,med Instr,apparatus
Industria
Surgical,med Instr,apparatus
Sitio web
www.alphatau.com
Sede
Jerusalem, Jerusalem, Isr
Fundado
-
Alpha Tau Medical Ltd is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker DRTS. The last closing price for Alpha Tau Medical was US$3.10. Over the last year, Alpha Tau Medical shares have traded in a share price range of US$ 1.75 to US$ 3.40.

Alpha Tau Medical currently has 69,670,612 shares in issue. The market capitalisation of Alpha Tau Medical is US$215.98 million. Alpha Tau Medical has a price to earnings ratio (PE ratio) of -7.41.

DRTS Últimas noticias

Más noticias

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

JERUSALEM, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...

18 Diciembre 2024
GlobeNewswire Inc.

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

JERUSALEM, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha...

17 Diciembre 2024
GlobeNewswire Inc.

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

JERUSALEM, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...

11 Diciembre 2024
GlobeNewswire Inc.

Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors Symposium

JERUSALEM, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...

06 Diciembre 2024
GlobeNewswire Inc.

Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

- Alpha DaRT® accepted into the prestigious Total Product Life Cycle Advisory Program (TAP) of the FDA, to accelerate market access to the Alpha DaRT® for patients with recurrent glioblastoma...

19 Noviembre 2024
GlobeNewswire Inc.

Alpha Tau to Participate in Citi’s 2024 Global Healthcare Conference and Piper Sandler’s 36th Annual Healthcare Conference

JERUSALEM, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...

13 Noviembre 2024
GlobeNewswire Inc.

Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

JERUSALEM, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-emitters cancer therapy Alpha...

21 Octubre 2024
GlobeNewswire Inc.

Alpha Tau Treats First Patient with Recurrent Lung Cancer

JERUSALEM, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...

10 Octubre 2024
GlobeNewswire Inc.

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

JERUSALEM, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...

20 Septiembre 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

22 Agosto 2024
Edgar (US Regulatory)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.0852.81923714763.0153.23432503.13640826CS
40.7632.47863247862.343.22.34627012.93864739CS
120.834.78260869572.33.22.11356192.6482372CS
260.8437.16814159292.263.21.75337202.4301471CS
520.13.3333333333333.41.75344262.62340574CS
156-8.45-73.160173160211.5520.651.75935268.84903502CS
260-8.45-73.160173160211.5520.651.75935268.84903502CS

DRTS - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Alpha Tau Medical?
El precio actual de las acciones de Alpha Tau Medical es US$ 3.10
¿Cuántas acciones de Alpha Tau Medical están en circulación?
Alpha Tau Medical tiene 69,670,612 acciones en circulación
¿Cuál es la capitalización de mercado de Alpha Tau Medical?
La capitalización de mercado de Alpha Tau Medical es USD 215.98M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Alpha Tau Medical?
Alpha Tau Medical ha negociado en un rango de US$ 1.75 a US$ 3.40 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Alpha Tau Medical?
El ratio precio/beneficio de Alpha Tau Medical es -7.41
¿Cuál es la moneda de reporte de Alpha Tau Medical?
Alpha Tau Medical presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Alpha Tau Medical?
El último beneficio anual de Alpha Tau Medical es USD -29.16M
¿Cuál es la dirección registrada de Alpha Tau Medical?
La dirección registrada de Alpha Tau Medical es KIRYAT HAMADA ST. 5, JERUSALEM, JERUSALEM, 9777605
¿Cuál es la dirección del sitio web de Alpha Tau Medical?
La dirección del sitio web de Alpha Tau Medical es www.alphatau.com
¿En qué sector industrial opera Alpha Tau Medical?
Alpha Tau Medical opera en el sector SURGICAL,MED INSTR,APPARATUS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
PHIOPhio Pharmaceuticals Corporation
US$ 3.98
(126.14%)
3.35M
EDBLEdible Garden AG Inc
US$ 0.4902
(106.23%)
19.77M
JDZGJIADE Ltd
US$ 0.8233
(55.31%)
909.86k
RUMRumble Inc
US$ 10.46
(45.48%)
625.82k
ADGMAdagio Medical Holdings Inc
US$ 2.38
(44.24%)
2.3M
TCBSTexas Community Bancshares Inc
US$ 11.005
(-27.07%)
206
WHLMWilhelmina International Inc
US$ 3.13
(-24.21%)
300
HSDTHelius Medical Technologies Inc
US$ 0.6928
(-23.87%)
154.1k
ONFOOnfolio Holdings Inc
US$ 1.23
(-23.13%)
6.32k
NIXXNixxy Inc
US$ 3.70
(-20.43%)
1
EDBLEdible Garden AG Inc
US$ 0.4902
(106.23%)
19.77M
LAESSEALSQ Corporation
US$ 3.65
(32.73%)
8.48M
NITON2OFF Inc
US$ 0.2225
(22.93%)
6.09M
PHIOPhio Pharmaceuticals Corporation
US$ 3.98
(126.14%)
3.35M
ABATAmerican Battery Technology Company
US$ 1.54
(35.09%)
3.06M

DRTS Discussion

Ver más
PonkenPlonken PonkenPlonken 17 horas hace
https://www.ourcrowd.com/startup-news/alpha-tau-100-complete-response-rate-in-skin-cancer-trial?
might become SOC in inoperable tumors - super tech - revolutionize radio
👍️0
PonkenPlonken PonkenPlonken 17 horas hace
has a lot of critical readouts coming soon - see below
neglected and forgotten...
👍️0
PonkenPlonken PonkenPlonken 5 días hace
https://www.alphatau.com/single-post/alpha-tau-healthcare-capital-corp-to-combine-and-create-a-1-billion-publicly-traded-company
👍️0
PonkenPlonken PonkenPlonken 3 semanas hace
Great Israeli company -- coming to life ahead of a few readouts
👍️0
theswordman theswordman 1 mes hace
3rd QTR update: 2+ years op cash. Trial expansion.
FDA accepted for TAP--Total Product Life Cycle Advisory Program (TAP)
FDA approval of an Investigational Device Exemption (IDE) application for cSCC

https://www.alphatau.com/single-post/alpha-tau-medical-announces-third-quarter-2024-financial-results-and-provides-corporate-update
👍️0
theswordman theswordman 2 meses hace
AlphaTau into the FDAs TPLC program: https://www.alphatau.com/single-post/alpha-tau-announces-acceptance-into-fda-s-total-product-life-cycle-advisory-program-to-accelerate-ma

Here is link that explains what that program helps with : https://www.fda.gov/medical-devices/how-study-and-market-your-device/total-product-life-cycle-advisory-program-tap
👍️0
theswordman theswordman 2 meses hace
1st lung cancer patient treated--https://www.alphatau.com/single-post/alpha-tau-treats-first-patient-with-recurrent-lung-cancer

“The treatment makes use of bronchoscopic endobronchial ultrasound to insert the Alpha DaRT sources.

examining its application to an organ such the lung, given its proximity to vital healthy organs, may hopefully open new doors to a global population of patients with otherwise poor treatment options
👍️0
theswordman theswordman 3 meses hace
Emory Univ wants another trial for subpopulation

https://www.alphatau.com/single-post/fda-approval-of-ide-to-initiate-multi-center-investigator-initiated-study-of-alpha-dart-in-immunoco
👍️0
theswordman theswordman 3 meses hace
The big boys are correct. Just a little off ontheir delivery and MOA

https://www.cnbc.com/2024/09/16/radiopharmaceuticals-race-heats-up-as-drugmakers-chase-novartis.html
👍️0
theswordman theswordman 4 meses hace
2nd qtr update

https://www.alphatau.com/single-post/alpha-tau-medical-announces-second-quarter-2024-financial-results-and-provides-corporate-update
👍️0
theswordman theswordman 6 meses hace
Atlanta TV discussing AlphaDart trial at Emory Univ.

https://www.atlantanewsfirst.com/2024/06/25/emory-doctor-hopeful-about-clinical-trial-new-skin-cancer-treatment/

https://clinicaltrials.gov/study/NCT05323253?term=alpha%20tau&intr=alpha%20dart&page=2&rank=20#study-overview
👍️0
theswordman theswordman 6 meses hace
Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

https://www.alphatau.com/single-post/alpha-tau-announces-publication-in-cancers-journal-of-long-term-safety-and-efficacy-data-in-multiple
👍️0
Monksdream Monksdream 6 meses hace
DRTS under $3
👍️0
theswordman theswordman 7 meses hace
https://www.alphatau.com/single-post/alpha-tau-medical-announces-first-quarter-2024-financial-results-and-provides-corporate-update
👍️0
theswordman theswordman 7 meses hace
https://www.alphatau.com/single-post/alpha-tau-announces-alpha-dart-treatment-of-first-patient-with-liver-metastases-of-colorectal-cancer
👍️0
theswordman theswordman 8 meses hace
Bassett is one of two Alpha DaRT trial sites in New York State, the other being Memorial Sloan Kettering Cancer Center in New York City.

https://www.allotsego.com/skin-cancer-treatment-trials-open/
👍️0
theswordman theswordman 8 meses hace
March Investor Deck

https://www.alphatau.com/_files/ugd/89ab89_701f2ad74a4c4684b223cb427cf79506.pdf
👍️0
theswordman theswordman 1 año hace
AlphaTau--Sidoti Conference

https://www.alphatau.com/single-post/alpha-tau-to-participate-in-sidoti-small-cap-conference

OR

https://www.meetmax.com/sched/event_98459/conference_presentations.html?bank_access=0&event_id=98459

This is from 07 DEC (THURS) @ 9:15 AM
👍️0
theswordman theswordman 1 año hace
Pancreatic Cancer Trial--early results
https://www.alphatau.com/single-post/highly-promising-interim-results-of-alpha-dart-treatment-of-advanced-pancreatic-cancer
👍️0
theswordman theswordman 1 año hace
Japan’s Pharmaceuticals and Medical Devices Agency (“PMDA”) has accepted Alpha Tau’s submission requesting shonin pre-market approval of Alpha DaRT in patients with recurrent head & neck cancer

https://www.alphatau.com/single-post/atm-submits-to-japanese-pmda-for-pre-market-approval-of-alpha-dart-for-recurrent-head-neck-cancer
👍️0
theswordman theswordman 1 año hace
CORP UPDATE

https://finance.yahoo.com/news/alpha-tau-medical-announces-third-213000260.html?.tsrc=rss
👍️0
theswordman theswordman 1 año hace
New video presentation. Updates about Hahn@SAB. New manuf facility.

👍️0
theswordman theswordman 1 año hace
Alpha Tau adds another manuf facility in U.S. So this is certainly getting ahead (cart before the horse??)
https://www.alphatau.com/single-post/atm-enters-into-long-term-lease-of-site-in-new-hampshire-for-second-u-s-manufacturing-facility

The Hudson site promises to be larger than our existing Lawrence site, and is expected to support our goals of materially scaling up capacity as well as achieving manufacturing redundancy
👍️0
theswordman theswordman 1 año hace
Hahn joins Science Advisor Board

https://www.marketscreener.com/quote/stock/ALPHA-TAU-MEDICAL-LTD-134583875/news/Alpha-Tau-Medical-Ltd-Announces-Stephen-M-Hahn-Joins-Scientific-Advisory-Board-45136482/
👍️0
theswordman theswordman 1 año hace
Latest DRTS presentation
👍️0
theswordman theswordman 1 año hace
2nd patient treated for inoperable pancreatic cancer. 1St was in Montreal

https://www.globenewswire.com/news-release/2023/09/14/2743253/0/en/Alpha-Tau-Treats-First-Patient-with-Advanced-Inoperable-Pancreatic-Cancer-at-Israel-s-Hadassah-Medical-Center.html
👍️0
Awl416 Awl416 1 año hace
Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT
👍️0
theswordman theswordman 2 años hace
New K O L event

👍️0
theswordman theswordman 2 años hace
CORP UPDATE

https://www.alphatau.com/single-post/alpha-tau-medical-announces-first-quarter-2023-financial-results-and-provides-corporate-update
👍️0
theswordman theswordman 2 años hace
With our Breakthrough Device Designation for the treatment of certain patients with squamous cell carcinoma, we look forward to swift accrual into our U.S. pivotal ReSTART trial, with the goal of bringing the Alpha DaRT closer to availability for patients as quickly as possible."

The results of the trial demonstrated that the treatment was successfully delivered to ten of ten patients, with a 100% CR observed at 12 and 24 weeks,

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2804784
👍️0
theswordman theswordman 2 años hace
New buy rating

https://beststocks.com/alpha-tau-medical-receives-buy-rating-and-hig/
👍️0
theswordman theswordman 2 años hace
Alpha Tau enrolled the 1st patrient in their 30 patient pancreatic cancer trial

https://www.clinicaltrials.gov/ct2/show/NCT04002479.

Read about the milestone here

https://www.alphatau.com/single-post/alpha-tau-jgh-announce-alpha-dart-treatment-of-first-patient-in-pancreatic-cancer-clinical-trial
👍️0
theswordman theswordman 2 años hace
New video

👍️0
theswordman theswordman 2 años hace
Treatment of 1st two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial

https://www.alphatau.com/single-post/treatment-of-1st-two-patients-in-its-pivotal-multicenter-recurrent-skin-cancer-restart-trial
👍️0
theswordman theswordman 2 años hace
Cash & equivalents balance of $105.4 million, with runway for at least two years

https://www.alphatau.com/single-post/alpha-tau-medical-announces-full-year-2022-financial-results-and-provides-corporate-update
👍️0
theswordman theswordman 2 años hace
https://www.alphatau.com/single-post/health-canada-authorization-for-alpha-dart-clinical-trial-for-the-treatment-of-liver-metastases
👍️ 1
theswordman theswordman 2 años hace
100% response rate!!!!!!!!!!!!!!!!!!!!!!!!!

👍️0
theswordman theswordman 2 años hace
Several good pieces of news

https://newsfilter.io/a/265287a70404d81a19c29eab7e95abca
👍️0
theswordman theswordman 2 años hace
Alpha Tau Medical Ltd. (the “Company”) hereby furnishes the following documents:

(i) notice and proxy statement with respect to the Company’s annual general meeting of shareholders (the “Meeting”) to be held at 4:30 p.m. (Israel time), on November 2, 2022, at the Company’s headquarters at 5 Kiryat Hamada St., Jerusalem 9777605, Israel, describing proposals to be voted upon at the Meeting, the procedure for voting in person or by proxy at the Meeting and various other details related to the Meeting; and
(ii) a proxy card for use in connection with the Meeting.

The proxy statement is furnished with this report of foreign private issuer on Form 6-K (this “Form 6-K”) as Exhibit 99.1 and the proxy cards are furnished with this Form 6-K Exhibits 99.2 and 99.3.

This Form 6-K is incorporated by reference into the Company’s registration statement on Form S-8 (File No. 333-264169).
👍️0
theswordman theswordman 2 años hace
GOOD READ!!!

https://medium.com/wadepthealth/washington-is-one-of-first-states-to-license-promising-new-cancer-treatment-59c42162e25b
👍️0
theswordman theswordman 2 años hace
18 JUL--11 AM EASTERN--free to register


https://finance.yahoo.com/news/alpha-tau-hosting-key-opinion-200100611.html
👍️0
theswordman theswordman 2 años hace
Patient, 60, is given alpha-radiation to target the tumor without harming healthy tissue in ‘historical’ procedure

https://nocamels.com/2022/06/israeli-researchers-use-breakthrough-tech-to-treat-prostate-cancer-for-first-time/
👍️0
theswordman theswordman 3 años hace
1st Prostate Cancer patient treated!!!!

https://www.prnewswire.com/news-releases/alpha-tau-announces-treatment-of-first-prostate-cancer-patient-with-alpha-dart-301573470.html
👍️0
theswordman theswordman 3 años hace
On June 16, 2022, Alpha Tau Medical Ltd. (the “Company”) issued a press release titled “Alpha Tau Announces Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site, Amended Radioactive License with Increased Capacity at Lawrence, MA Site.” A copy of this press release is attached to this Form 6-K as Exhibit 99.1.


https://newsfilter.io/a/90df70ad4fbbeb233fae5d6cea6e9dce
👍️0
theswordman theswordman 3 años hace
https://www.prnewswire.com/news-releases/alpha-tau-announces-fda-approval-of-ide-to-initiate-multi-center-pivotal-study-of-alpha-dart-in-recurrent-cutaneous-scc-301564017.html
👍️0
theswordman theswordman 3 años hace
NEW MAY 2022 INVESTOR PRESENTATION

Link goes to webpage for PDF download

https://www.alphatau.com/events
👍️0
theswordman theswordman 3 años hace
DRTS: Alpha Tau: First Alpha DaRT Patients Treated in France as Part of Alpha DaRT Multicenter Skin Cancer Trial

https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20220523090518DRTS&utm_campaign=inplay&utm_medium=social&utm_source=twitter&utm_content=view_page
👍️0
theswordman theswordman 3 años hace
Form F-1 filed

https://newsfilter.io/a/a2246fdd4e4ed658cd4c86741101f8c0
👍️0
theswordman theswordman 3 años hace
CantorFitz initiates coverage of AlphaTau

https://biotuesdays.com/2022/04/14/cantor-starts-alpha-tau-medical-at-ow-pt-20/
👍️0
theswordman theswordman 3 años hace
https://seekingalpha.com/article/4500989-alpha-tau-treating-cancer-with-precision-alpha-radiation?utm_source=stck.pro&utm_medium=referral
👍️0

Su Consulta Reciente

NASDAQ
DRTS
Alpha Tau Medical
TG
A3K810
Danone
NYSE
RBC
RBC Bearings
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados